Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.21+0.05 (+1.20%)
Close on Nov 13, 2026Market cap $449.08MP/E –Yield –
Relmada Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Relmada Therapeutics's total debt was $3.19M at Sep 30, 2018. For fiscal 2018 it was $2.66M.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | $2.66M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $3.19M | +370.3% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $2.66M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $1.58M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $1.28M | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $678.88K | – |
See a number that looks wrong?